Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years

The study start date was the earliest Emergency Use Authorization date for the BNT162b2 vaccination for each age group: for ages 5 to 11 years, October 29, 2021; ages 12 to 15 years, May 10, 2021; and ages 16 to 17 years, December 11, 2020. For the data cut dates, CVS Health data were available through May 31, 2022; HealthCore data through May 6, 2022; and Optum data through June 25, 2022.

eTable 3. Outcomes, Age Groups, Settings, Clean Windows, Risk Windows, and Analysis Type for the Pediatric Population (Ages 5-17)

eTable 4. Sequential Testing Results in Health Plan Members Aged 5-17 years by Outcome Following BNT162b2 All Doses (Primary Series, Dose 1, Dose 2, and Third/Booster Dose) in CVS Health, HealthCore, and Optum Databases

Hu M, Wong HL, Feng Y, et al. Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years. JAMA Pediatr. Published online May 22, 2023. doi:10.1001/jamapediatrics.2023.1440

Question  Does active monitoring detect potentially elevated risk of health outcomes after BNT162b2 COVID-19 vaccination in the US pediatric population aged 5 to 17 years?

Leave a Comment